Tuesday, 6 May 2014

Americord funds clinical trial investigating human umbilical cord stem cells for treating Alzheimer's

Americord logo
Americord recently announced that it has provided funding to MEDIPOST, a stem cell biotechnology company, to support their clinical trial investigating the use of NEUROSTEM-AD® in the treatment of patients with Alzheimer's.

NEUROSTEM-AD® is a treatment agent for Alzheimer's Disease that uses human umbilical cord blood-derived mesenchymal stem cells.

This is the first donation that Americord has made under its recently launched corporate giving program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

"At Americord, we are committed to assisting the world's leading scientists as they pursue cutting edge stem cell-based therapies for diseases and conditions that have long-proved to be difficult or impossible to treat. We are thrilled to make a donation to MEDIPOST to support their research into the treatment of Alzheimer's Disease with a stem cell-based therapy." said Americord CEO Martin Smithmyer.

MEDIPOST's study began in February 2014 and is anticipated to be completed by December 2015. It is registered with ClinicalTrials.gov in accordance with best practices and requirements of the U.S. Food and Drug Administration.


No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !